

## TE Possible Alternative to Liver Biopsy

BY MIRIAM E. TUCKER

NEW YORK — Transient elastography correlated with aminotransferase levels in a cross-sectional study of 22 adolescent and young women with Turner's syndrome.

Transient elastography (TE), a novel technique for measuring liver stiffness, has been widely validated as a noninvasive alternative to liver biopsy for evaluating hepatic fibrosis in patients with chronic hepatitis C. It has not been used in Turner's syndrome (TS) patients, in whom liver involvement is common.

Although liver biopsy is the standard method for assessing liver fibrosis, it is an invasive and very expensive procedure that can incur life-threatening complications, and therefore can't be used as a tool to screen or monitor liver function in all TS patients.

TE is a painless procedure in which an ultrasound transducer probe mounted on a vibrator issues a wave through underlying tissues. Pulse-echo ultrasound acquisition is used to follow the propagation of the shear wave and to measure its velocity, which is directly related to tissue stiffness. The stiffer the tissue, the faster the shear wave propagates (*J. Hepatol.* 2008;48:835-47).

The findings from this small study—which will require replication in a larger number of patients—suggest that TE could be used to identify patients with elevated aminotransferase levels who might qualify for more invasive tests and possibly liver biopsy to better stage the etiology of liver involvement, Dr. Maria Francesca Messina said at a joint meeting of the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology.

The procedure could be used to monitor the progression of liver dysfunction in TS patients without exposing them to the significant clinical risks of more invasive procedures, Dr. Messina said.

The 22 TS patients had a mean age of 20.9 years and full pubertal development (spontaneous or pharmacologic). All fasted and underwent TE along with biochemical testing. Six patients were found to have elevated aminotransferase levels.

The mean liver stiffness for the entire group was 4.5 kilopascal (less than 7 kPa is generally considered mild or normal), and was significantly higher among those with elevated transaminase levels compared with those who had normal liver function (6 vs. 4 kPa), said Dr. Messina of the department of pediatrics at the University of Messina (Italy).

The TE device, called FibroScan, is marketed by France-based Echosens International ([www.echosens.com](http://www.echosens.com)). The company did not fund this study.

Dr. Messina stated that she has no relevant financial disclosures. ■

## Problems Seen in Type 1 Adolescents

BY MIRIAM E. TUCKER

NEW YORK — Early diabetes complications were seen in a significant proportion of 821 adolescents with type 1 diabetes for just 2-5 years.

Up to 1 in 5 of the adolescents had early indicators of eye, kidney, and/or nerve complications. The findings support early screening for diabetes complications as recommended by some—but not all—published consensus guidelines, Dr. Yoon

Hi Cho said at a joint meeting of the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology.

The 821 patients were all seen at the Children's Hospital at Westmead, Sydney, between 1990 and 2006. They were aged 11-17 years, with a type 1 diabetes duration of 2-5 years (median 3.8) and a median hemoglobin A<sub>1c</sub> level of 8.9%.

Early retinopathy, defined as one microaneurysm or hemorrhage on seven-

field stereoscopic fundus photography, was detected in 9% of the patients. Albumin excretion rate (AER) was measured for overnight urine collections. Early nephropathy, defined as a borderline elevation of AER of 7.5 to less than 20 mcg/min, was seen in 22% of the adolescents. Microalbuminuria, defined as an AER of 20 mcg/min or greater, was identified in 3%. Peripheral nerve abnormalities on thermal and vibration thresholds at the feet—mea-

## For your adult patients with type 2 diabetes



### Indication and Important Limitations of Use

ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

ONGLYZA has not been studied in combination with insulin.

### Important Safety Information

- **Use with Medications Known to Cause Hypoglycemia:** Insulin secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a lower dose of the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA
- **Macrovascular Outcomes:** There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug

**Most common adverse reactions** (regardless of investigator assessment of causality) reported in  $\geq 5\%$  of patients treated with ONGLYZA and more commonly than in patients treated with control were upper respiratory tract infection (7.7%, 7.6%), headache (7.5%, 5.2%), nasopharyngitis (6.9%, 4.0%) and urinary tract infection (6.8%, 6.1%). When used as add-on combination therapy with a thiazolidinedione, the incidence of peripheral edema for ONGLYZA 2.5 mg, 5 mg, and placebo was 3.1%, 8.1% and 4.3%, respectively.